Clinical Trials
19 trialsNCT07622784 2026-06-03
Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07385612 2026-05-29
REFRACT-LyMA
Nantes University Hospital
Not yet recruiting
NCT07616089 2026-05-29
FXS0683-001
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1 Not yet recruiting
NCT07593482 2026-05-18
FC-BALANCE
Swiss Cancer Institute
Phase 2 Not yet recruiting
NCT07588698 2026-05-15
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
NCT07451054 2026-05-14
CD45BE-HSPC + CART-45 Cells
University of Pennsylvania
Phase 1 Not yet recruiting
NCT07101328 2026-05-13
BAF_FRontier-1
Eli Lilly and Company
Phase 1 Not yet recruiting
NCT07584850 2026-05-13
Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ruijin Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT07569965 2026-05-06
FRONTIER
Miltenyi Biomedicine GmbH
Phase 2 Not yet recruiting
NCT06970496 2026-05-05
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT07563543 2026-05-04
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1 Not yet recruiting
NCT07546630 2026-04-29
Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
Phase EARLY_PHASE1 Not yet recruiting
NCT07539688 2026-04-20
Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT07532525 2026-04-16
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
University of Michigan Rogel Cancer Center
Phase 1 Not yet recruiting
NCT07520006 2026-04-13
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1/2 Not yet recruiting
NCT07516093 2026-04-08
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Nurix Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT07506668 2026-04-02
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Affiliated Hospital of Nantong University
Phase 1/2 Not yet recruiting
NCT07502872 2026-03-31
TPG
Brown University
Phase 2 Not yet recruiting
NCT07477366 2026-03-17
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
ImmunityBio, Inc.
Phase 2 Not yet recruiting